Dempster R P, Robinson C M, Harrison G B
Mallinckrodt Veterinary New Zealand Ltd, Upper Hutt, New Zealand.
Parasitol Res. 1996;82(4):291-6. doi: 10.1007/s004360050116.
Genetically modified Escherichia coli expressing the Taenia ovis fusion protein GST-45W(B/X) as inclusion bodies were grown in volumes ranging up to 1000 l. Bacteria were inactivated by heat or chemical treatment without affecting immunogenicity. The fusion protein was recovered in a highly immunogenic form from washed inclusion bodies and from urea-solubilised inclusion bodies. The fusion protein was found to be stable in solution after storage at 4 degrees C for up to 2 years. Vaccines formulated with fusion protein from urea-soluble inclusion bodies gave consistently high protection (89-100%) against challenge infection. The methods described enabled the production of sufficient vaccine for large field trials. These trials generated the data required for product registration and manufacture of a vaccine to prevent T. ovis infection in sheep.
表达绵羊带绦虫融合蛋白GST - 45W(B/X)并形成包涵体的转基因大肠杆菌在高达1000升的体积中培养。细菌通过加热或化学处理灭活，而不影响其免疫原性。融合蛋白以高度免疫原性的形式从洗涤后的包涵体和尿素溶解的包涵体中回收。发现融合蛋白在4℃储存长达2年后在溶液中稳定。用来自尿素可溶包涵体的融合蛋白配制的疫苗对攻毒感染始终提供高保护率（89 - 100%）。所述方法能够生产足够的疫苗用于大型田间试验。这些试验产生了产品注册和生产预防绵羊绵羊带绦虫感染疫苗所需的数据。
